Research and Teaching Assistant
Céline Moret obtained a Master's degree in Biology in 2006 at the University of Geneva, a Master's degree in Bioinformatics in 2011 and a PhD in Biomedical Sciences with a specialization in Bioethics in 2019. She completed her PhD thesis at the Institute for Ethics, History, and the Humanities (IEH2) under the co-supervision of Prof. Samia Hurst and Prof. Alex Mauron on the topic of informed consent in the context of high-throughput sequencing genetic analyses. She is currently working at the IEH2 on the scientific validity of direct-to-consumer medical genetic tests and client information. Céline Moret is a member of the medical and scientific board of ProRaris.
Before joining the IEH2, she was in charge of the French-speaking patient advice service of the Retina Suisse association from 2007 to 2013.
- Informed consent in the context of high-throughput sequencing genetic analyses
- Ethical issues of direct-to-consumer genetic testing
- "Bioethics" course of Prof. Samia Hurst and Dr. Christine Clavien, University of Geneva
- "Genes and vision" course of Prof. Yvan Arsenijevic, University of Lausanne
Blasimme, A., Moret, C., Hurst, S. A. & Vayena, E. Informed Consent and the Disclosure of Clinical Results to Research Participants. Am J Bioeth 17, 58–60 (2017).
Moret, C., Mauron, A., Fokstuen, S., Makrythanasis, P. & Hurst, S. A. Defining categories of actionability for secondary findings in next-generation sequencing. J Med Ethics (2016). doi:10.1136/medethics-2016-103677
Moret, C., Hurst, S. A. & Mauron, A. Variants of Unknown Significance and Their Impact on Autonomy. Am J Bioeth 15, 26–28 (2015).
Gerbault, P., Moret, C., Currat, M. & Sanchez-Mazas, A. Impact of selection and demography on the diffusion of lactase persistence. PLoS ONE 4, e6369 (2009).
"Defining categories of actionability for secondary findings in next-generation sequencing", International Association of Bioethics world congress, Edimbourg 2016
"La loi relative à la recherche sur l'être humain du point de vue des patients", symposium of the Swiss Clinical Trial Organisation, Bern 2016
"Points à considérer avant d'entrer dans un essai clinique", Rare Disease Day, Fribourg 2015